How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,365 results for

Medication Causes of Dyspepsia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients

of administration of an antineoplastic therapy. Chemotherapy/antineoplastic therapy block: series of consecutive days that antineoplastic agents are given within a treatment plan or protocol Emetogenicity: the propensity of an agent to cause nausea, vomiting or retching. Please refer to the POGO Guideline classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients for information regarding the emetogenicity of specific agents. 1, 2 ? High emetic potential: greater (...) : Additional Literature Search: Dronabinol and Levomepromazine 142 Appendix E: Quality of Evidence and Strength of Recommendation 148 Appendix F: Tables of Included Studies 149 F.1 Summary of studies used to inform recommendation #2a 149 F.1a Highly emetogenic antineoplastic therapy as ranked by POGO Guideline for Classification of the Acute Emetogenic Potential of antineoplastic Medication in Pediatric Cancer Patients 5 Version date: February 28, 2013 F.1b Highly emetogenic antineoplastic therapy

2013 SickKids Supportive Care Guidelines

22. Dyspepsia - proven functional

with a Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (2015). July 2015 — minor update. The prescribing information section for clarithromycin has been re-written for clarity. May 2014 — minor update. Domperidone has been removed as a treatment option following the publication of the European Medicines Agency (EMA) document Restrictions on the use of domperidone-containing medications (2014). September 2013 — minor update. Metoclopramide has been removed as a treatment option (...) the person's medication The recommendation on self-treating with antacid and/or alginate therapy is extrapolated from NICE recommendations on the management of gastro-oesophageal reflux disease (GORD), as there is evidence that antacids are no more effective than placebo in treating functional dyspepsia symptoms [ ]. NICE noted that antacid and/or alginate medication is often prescribed by primary healthcare professionals, and is often used as over-the-counter medication. It may provide short-term symptom

2018 NICE Clinical Knowledge Summaries

23. Dyspepsia - proven peptic ulcer

is increased in older age groups, people with co-morbidities, and people taking medication such as nonsteroidal anti-inflammatory drugs (NSAIDs) or anticoagulants. Possible complications include [ ; ; ]: Haemorrhage — acute massive haemorrhage may be life-threatening with a case fatality rate of 5–10%, and chronic bleeding may cause iron deficiency anaemia. See the CKS topic on for more information. Perforation — this may cause peritonitis which may be life-threatening, with a mortality rate of up to 20 (...) with functional dyspepsia, as this may reduce symptoms in the short-term [ ]. Reviewing the person's medication The recommendation on self-treating with antacid and/or alginate therapy is extrapolated from NICE recommendations on the management of gastro-oesophageal reflux disease (GORD) [ ]. NICE noted that antacid and/or alginate medication is often prescribed by primary healthcare professionals, and is often used as over-the-counter medication. It may provide short-term symptom relief, but does not prevent

2018 NICE Clinical Knowledge Summaries

24. Effects of Bu-Zhong-Yi-Qi-Tang for the treatment of functional dyspepsia: a feasibility study protocol Full Text available with Trip Pro

Effects of Bu-Zhong-Yi-Qi-Tang for the treatment of functional dyspepsia: a feasibility study protocol Bu-Zhong-Yi-Qi-Tang (BZYQT) has long been used for the treatment of severe weakness caused by general fatigue, loss of appetite, or indigestion. The aim of this feasibility study is to assess the effectiveness and safety of BZYQT for the treatment of functional dyspepsia (FD) with spleen qi deficiency.This study will be conducted at a single center as a prospective, nonrandomized, nonblinded (...) , single-arm feasibility study. A total of 30 participants diagnosed with FD in accordance with the Rome III criteria will be enrolled. All patients will receive BZYQT for 4 weeks. The primary outcome is the change in the Nepean Dyspepsia Index-Korean version (NDI-K) scores between the baseline and 4-week images. The secondary outcomes include the tongue coating thickness, blood parameters, and BZYQT Questionnaire score. The NDI-K score will be acquired four times, at Weeks 0 (baseline), 2 (during

2017 Integrative medicine research

25. Celecoxib versus Non-COX-2 Selective Non-steroidal Anti-inflammatory Drugs and Proton Pump Inhibitors: A Review of the Clinical Effectiveness, Safety, and Cost Effectiveness

/products/2/67/AnalgesicsExecSum.pdf 9. Health Canada. Notice of Compliance (NOC) [Internet]. Ottawa: Health Canada; 1994 -; 2011 [cited 2011 Dec 1]. Available from: http://webprod3.hc-sc.gc.ca/noc-ac/start- debuter.do?lang=eng 10. Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease: scientific report [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2007 Mar. [cited 2011 Dec 5]. (Optimal therapy report; vol. 1 no. 2). Available (...) -effectiveness of celecoxib and nsNSAIDs plus PPIs. A decision tree model was developed, with a one year time horizon, to simulate cohorts within celecoxib, nsNSAIDs and nsNSAIDs plus PPIs. The effectiveness of the different active agents of NSAIDs in therapeutically relevant doses was assumed to be the same. On the other hand, differences were observed in the side effect profile of the drugs, such as GI ulcers and bleeding. The direct medical costs and costs related to adverse events were calculated

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

26. To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Rela

with AE's and serious adverse events (SAEs),Part 1 [ Time Frame: up to 4.5 years ] An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly (...) achieving Minimal residual disease (MRD) negativity, Part 2, Treatment A [ Time Frame: Every 4 weeks up to 4.5 years ] MRD negativity defined as the percentage of subjects who are MRD negative. Number of subjects with AE's and SAE's, Part 2 [ Time Frame: up to 4.5 years ] An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical

2018 Clinical Trials

27. The role of endoscopy in dyspepsia

drugs, a trial of antispasmodics, dietary and lifestyle changes, prokinetic agents, sucralfate, simethicone, tricyclic antidepressants, selective serotonin reuptake inhibitors, and cognitive behavior therapy. 51,52 More research is required to under- stand the pathophysiology of symptoms in these patients and the role of medications and other therapies. Other conditions that may cause upper abdominal pain or discomfort (which may be confused with dyspepsia) should be considered, including irritable (...) . Dyspepsia symptoms Age =50 and/or alarm symptoms Trial of PPI EGD yes No findings No improvement No improvement Findings Negative no EGD Evaluate for other causes, Dietary modifications, Tricyclics, SSRI, Psychological therapy, Prokinetics, Sucralfate, Bismuth Treat specific findings Test and treat H pylori* Figure 1. Suggested algorithm for evaluation of dyspepsia. A 4- to 8-week trial of a proton pump inhibitor (PPI) after test and treat for Helicobacter pylori nonresponders has not been formally

2015 American Society for Gastrointestinal Endoscopy

28. Carbon-13 Urea Breath Test for Helicobacter Pylori Infection in Patients With Uninvestigated Ulcer-Like Dyspepsia

Determinants 9 Carbon-13 Urea Breath Test for Helicobacter Pylori Infection in Patients with Uninvestigated Ulcer-Like Dyspepsia: OHTAC Recommendation. October 2013; pp. 1-10 5 Background An evidence-based analysis (http://www.hqontario.ca/en/documents/eds/2013/full-report-urea-breath-test.pdf) was conducted by the Medical Advisory Secretariat Collaboration to answer the following research question: ? What is the diagnostic accuracy and clinical utility of the carbon-13 urea breath test ( 13 C UBT (...) and no alarm features. In head-to-head comparisons with serology, 13 C UBT has comparable sensitivity but higher specificity (GRADE: Low) Safety No safety concerns were identified Burden of Illness Dyspepsia is a common condition reported by 29% of Canadians. Helicobacter pylori is one of the causes of dyspepsia. The estimated prevalence of H. pylori infection in Ontario is 23%, with older people and immigrants at higher risk. Approximately one third of patients presenting to primary care with dyspepsia

2013 Health Quality Ontario

29. Dyspepsia - pregnancy-associated

and anorexia. Alarm features (for example haematemesis, weight loss, dysphagia) that might suggest more serious underlying disease. Previous history of dyspepsia or reflux symptoms. Aggravating factors such as lying supine, eating a meal, and use of medications which can contribute to dyspepsia, such as nonsteroidal anti-inflammatory drugs. Features suggesting an illness unrelated to pregnancy (for example symptoms of fever, rigors, vomiting, and malaise). For more information, see the section (...) on . Treatments already tried, especially over-the-counter medication (for example antacids). Examination is usually normal. Investigations are generally not necessary. Where they are required, they are usually carried out in secondary care and may include: Manometry and pH probes. An upper GI endoscopy. Non-invasive testing for Helicobacter pylori , which may be delayed until after delivery. Basis for recommendation Basis for recommendation The information that dyspepsia in pregnancy is predominantly caused

2017 NICE Clinical Knowledge Summaries

30. Dyspepsia - proven GORD

and anxiety The recommendation on assessing for and managing associated stress and anxiety is extrapolated from the NICE recommendation to offer psychological treatments to people with functional (non-ulcer) dyspepsia, as this may reduce symptoms in the short-term [ ]. This is also supported by expert opinion in a review article on dyspepsia [ ]. Reviewing the person's medication The recommendation on considering reducing or stopping a variety of drugs that may reduce LOS pressure and cause or exacerbate (...) and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (2015). May 2014 — minor update. Domperidone has been removed as a treatment option following the publication of the European Medicines Agency (EMA) document Restrictions on the use of domperidone-containing medications (2014). September 2013 — minor update. Metoclopramide has been removed as a treatment option following the publication of a European Medicines Agency (EMA) document highlighting the risk of neurological adverse effects (2013

2017 NICE Clinical Knowledge Summaries

31. Letermovir (Prevymis) - to prevent illness caused by cytomegalovirus (CMV) in adults having an allogeneic haematopoietic stem cell transplant

Letermovir (Prevymis) - to prevent illness caused by cytomegalovirus (CMV) in adults having an allogeneic haematopoietic stem cell transplant 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 9 November 2017 EMA/CHMP/490007/2017 (...) . Problem statement 8 2.2. Quality aspects 9 2.2.1. Introduction 9 2.2.2. Active Substance 9 2.2.3. Finished Medicinal Product 12 2.2.4. Discussion on chemical, pharmaceutical and biological aspects 17 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects 17 2.2.6. Recommendation(s) for future quality development 17 2.3. Non-clinical aspects 18 2.3.1. Introduction 18 2.3.2. Pharmacology 18 2.3.3. Pharmacokinetics 20 2.3.4. Toxicology 22 2.3.5. Ecotoxicity/environmental risk

2018 European Medicines Agency - EPARs

32. The Diagnosis and Treatment of Functional Dyspepsia. Full Text available with Trip Pro

. The etiology of the disorder is heterogeneous and multifactorial. Contributory causes include motility disturbances, visceral hypersensitivity, elevated mucosal permeability, and disturbances of the autonomic and enteric nervous system. There is as yet no causally directed treatment for functional dyspepsia. Its treatment should begin with intensive patient education regarding the benign nature of the disorder and with the establishment of a therapeutic pact for long-term care. Given the absence (...) of a causally directed treatment, drugs to treat functional dyspepsia should be given for no more than 8-12 weeks. Proton-pump inhibitors, phytotherapeutic drugs, and Helicobacter pylori eradication are evidence-based interventions. For intractable cases, tricyclic antidepressants and psychotherapy are further effective treatment options.The impaired quality of life of patients with functional dyspepsia implies the need for definitive establishment of the diagnosis, followed by symptom-oriented treatment

2018 Deutsches Arzteblatt international

33. The Predictive Value of Alarm Symptoms in Patients With Dyspepsia Based on Roman IV

the underlying cause of dyspepsia,but a number of alarm features have been suggested as indicating patients at higher risk for serious disease. The predictive value of alarm symptoms still require more researches. Rome IV introduced more precisely define the minimal thresholds for frequency and severity of each individual symptom, primarily for scientific purposes,but data still need to be collected to define thresholds based on the frequency and/or severity of symptoms that impair quality of life.A cross (...) syndrome characterized by chronic and recurrent gastroduodenal symptoms in the absence of any organic or metabolic disease that is likely to explain the symptoms.Functional dyspepsia has a high incidence in the population.Clinical diagnosis is notoriously unreliable in diagnosing the underlying cause of dyspepsia,but a number of alarm features have been suggested as indicating patients at higher risk for serious disease.However, previous studies noted that the sensitivity of alarm features

2018 Clinical Trials

34. Effect of Gingest on Symptoms of Dyspepsia

in order to exclude the presence of structural or biochemical causes of dyspepsia. Participants are asked to avoid all foods containing ginger within the 14 days prior to study product administration and throughout the study. A list of foods high in ginger will be provided to subjects as a guide and this list will be reviewed at each visit. Subject with known allergy to components of the test product Any medical condition deemed exclusionary by the Principal Investigator Subject has a history of drug (...) of sensation and movement (peristalsis) in the upper digestive tract. A diagnosis of functional dyspepsia is determined when there is no evidence of structural disease and there have been at least three months of one or more of the following (with onset at least six months earlier). Ginger (Zingiber officinale) is traditionally used to treat a number of medical conditions, including those affecting the digestive tract, such as dyspepsia, flatulence, nausea and abdominal pain. Recent human clinical studies

2018 Clinical Trials

35. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient Guidelines for the Provision and Assessment of Nutrition Sup... : Critical Care Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me on this computer Register for a free account (...) my selection doi: 10.1097/CCM.0000000000001525 Special Article Free Supplemental Digital Content is available in the text. 1 Nutrition Support Specialist, Barnes Jewish Hospital, St. Louis, MO. 2 Department of Medicine, University of Louisville, Louisville, KY. 3 Chief Division of General Surgery, Oregon Health and Science University, Portland, OR. 4 Critical Care Dietitian, Portland VA Medical Center, Portland, OR. 5 Clinical Nurse Specialist: Wound, Skin, Ostomy, UW Health University

2016 Society of Critical Care Medicine

36. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient

and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Volume 40 Issue 8 Journal of Parenteral and Enteral Nutrition pages: 1200-1200 First Published online: September 15, 2016 Corresponding Author E-mail address: Department of Medicine, University of Louisville, Louisville, Kentucky Beth Taylor and Steven McClave are co–first authors of this article. Stephen A. McClave, MD (...) , Department of Medicine, University of Louisville, Louisville, KY. Email: Charlene Compher, RD, PhD, Professor of Nutrition Science, University of Pennsylvania School of Nursing, Philadelphia, PA, USA. Email: Nutrition Support Specialist, Barnes Jewish Hospital, St Louis, Missouri Beth Taylor and Steven McClave are co–first authors of this article. Chief Division of General Surgery, Oregon Health and Science University, Portland, Oregon Critical Care Dietitian, Portland VA Medical Center, Portland, Oregon

2016 American Society for Parenteral and Enteral Nutrition

37. Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

/ by David Kinnison on 11/09/2012e4S Immunosuppressive Drugs in Lung Disease and Lung Transplant Patients disease and for lung transplant recipients. Early rec- ognition of conditions that require immunosuppressive therapy and prompt administration of immunosup- pressive agents can prevent or minimize tissue injury and prevent irreversible decline in organ function. Because these medications can be harmful, timely detection and remediation of clinically signi? cant side effects can improve the bene? t (...) Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients CHEST Evidence-Based Medicine journal.publications.chestnet.org CHEST / 142 / 5 / NOVEMBER 2012 e1S 3.1 Anti-Tumor Necrosis Factor- a (TNF- a ) Agents Objectives: Immunosuppressive pharmacologic agents prescribed to patients with diffuse inter- stitial and in? ammatory lung disease and lung transplant recipients are associated with poten- tial risks for adverse reactions. Strategies

2012 American College of Chest Physicians

38. Vagal Nerve Blockade for Obesity: VBLOC Therapy Using the Maestro RC2 Device

to bring about sustained and clinically significant weight loss in patients for whom drug therapy or bariatric surgery are not indicated, or who do not want to undergo bariatric procedures that are invasive, irreversible, and bring a higher risk of short- and long-term adverse events. The Maestro RC2 device, a vagal nerve blocker positioned laparoscopically, could satisfy the need for such an alternative approach to inducing weight loss in obese patients. Compared with evidence concerning available (...) daily battery checks and undertake recharging as needed. The device can be removed if necessary. Regulatory Status Toward the end of 2015, EnteroMedics will submit an application to Health Canada for regulatory approval of VBLOC therapy for adult obesity using the Maestro RC2 device (Dan Cohen, EnteroMedics Inc., St. Paul, MN: personal communication, 2015 March). The US Food and Drug Administration (FDA) recently approved this first-of-kind device to induce weight loss via vagal nerve blockade

2015 CADTH - Issues in Emerging Health Technologies

39. Vagal Nerve Blockade for Obesity: VBLOC Therapy Using the Maestro RC2 Device

to bring about sustained and clinically significant weight loss in patients for whom drug therapy or bariatric surgery are not indicated, or who do not want to undergo bariatric procedures that are invasive, irreversible, and bring a higher risk of short- and long-term adverse events. The Maestro RC2 device, a vagal nerve blocker positioned laparoscopically, could satisfy the need for such an alternative approach to inducing weight loss in obese patients. Compared with evidence concerning available (...) daily battery checks and undertake recharging as needed. The device can be removed if necessary. Regulatory Status Toward the end of 2015, EnteroMedics will submit an application to Health Canada for regulatory approval of VBLOC therapy for adult obesity using the Maestro RC2 device (Dan Cohen, EnteroMedics Inc., St. Paul, MN: personal communication, 2015 March). The US Food and Drug Administration (FDA) recently approved this first-of-kind device to induce weight loss via vagal nerve blockade

2015 CADTH - Issues in Emerging Health Technologies

40. Prescribing patterns of dependence forming medicines

included in the analysis see Appendix 30. GABAergic medicines are approved for the treatment of a range of conditions including epilepsy, neuropathic pain, fibromyalgia, generalised anxiety disorder and restless drug syndrome. Off-label uses include migraine, social phobia, panic disorder, mania, bipolar disorder and alcohol withdrawal. GMS General Medical Services GP General Practitioner GPRD General Practice Research Database HES Hospital Period Statistics HSCIC Health and Social Care Information (...) website. In addition, references cited in articles previously found located on the US National Library of Medicine National Institutes of Health (NCBI/PubMed.gov) website. Papers were identified with the following search terms: ‘benzodiazepines’, ‘Z-drugs’, ‘prescribing trends’, ‘opiates’, ‘hypnotics’, ‘anxiolytics’, ‘analgesics’, ‘GABAergic’, ‘pregabalin’, ‘gapapentin’, ‘opioids’, and ‘dependence forming medication’. The focus was on studies published after 2009, so as to provide an update

2017 Public Health Research Consortium

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>